» Articles » PMID: 35229334

Comparative Efficacy of an Optimal Exam Between Ultrasound Versus Abbreviated MRI for HCC Screening in NAFLD Cirrhosis: A Prospective Study

Abstract

Background: Retrospective studies report that visualisation of the liver may be severely limited using ultrasound (US), potentially contributing to diminished sensitivity for detection of hepatocellular carcinoma (HCC) among patients with nonalcoholic fatty liver disease (NAFLD) and cirrhosis, but there are limited prospective data.

Aims: To compare liver visualisation scores prospectively for US and abbreviated hepatobiliary phase (HBP) magnetic resonance imaging (AMRI) in a cohort of participants with NAFLD cirrhosis and a clinical indication for HCC surveillance.

Methods: This prospective multicenter study included 54 consecutive participants (67% women) with NAFLD cirrhosis who underwent contemporaneous US as well as HBP-AMRI with gadoxetic acid. Primary outcome was the proportion of imaging examinations with severe limitations in liver visualisation (visualisation score C) compared head-to-head between US and AMRI.

Results: The mean (± standard deviation) age was 63.3 years (±8.4) and body mass index was 32.0 kg/m (±6.0). Nineteen participants (35%) had severe visualisation limitations on US, compared with 10 (19%) with AMRI, p < 0.0001. Nine (17%) participants had <90% of the liver visualised on US, compared with only 1 (2%) participant with AMRI, p < 0.0001. Obesity was a strong and independent predictor for severe visualisation limitation on US (OR 5.1, CI 1.1-23.1, p = 0.03), after adjustment for age, sex and ethnicity.

Conclusion: More than one-third of participants with NAFLD cirrhosis had severe visualisation limitations on US for HCC screening, compared with one-sixth on AMRI. US adequacy should be reported in all clinical studies and when suboptimal then AMRI may be considered for HCC screening.

Citing Articles

Metabolic dysfunction-associated steatotic liver disease in adults.

Huang D, Wong V, Rinella M, Boursier J, Lazarus J, Yki-Jarvinen H Nat Rev Dis Primers. 2025; 11(1):14.

PMID: 40050362 DOI: 10.1038/s41572-025-00599-1.


Risk-stratified hepatocellular carcinoma surveillance in non-cirrhotic patients with MASLD.

Mi K, Ye T, Zhu L, Pan C Gastroenterol Rep (Oxf). 2025; 13:goaf018.

PMID: 39980834 PMC: 11842057. DOI: 10.1093/gastro/goaf018.


Gadoxetic acid disodium (Gd-EOB-DTPA) contrast-enhanced abbreviated magnetic resonance imaging (MRI) for hepatocellular carcinoma surveillance in at-risk patients: a multi-center study in China.

He X, Li Y, Han D, Zhou Y, Zhang J, Xu Q Quant Imaging Med Surg. 2024; 14(12):8520-8537.

PMID: 39698720 PMC: 11651963. DOI: 10.21037/qims-24-941.


Performing liver imaging at a high level: quality and adequacy in LI-RADS.

Hong C, M Cunha G, Yokoo T, Roudenko A, Kelm Z, Fung A Abdom Radiol (NY). 2024; .

PMID: 39614884 DOI: 10.1007/s00261-024-04679-w.


Exam quality of ultrasound and dynamic contrast-enhanced abbreviated MRI and impact on early-stage HCC detection.

Seif El Dahan K, Yokoo T, Mendiratta-Lala M, Fetzer D, Davenport M, Daher D Abdom Radiol (NY). 2024; .

PMID: 39542949 DOI: 10.1007/s00261-024-04674-1.


References
1.
Zhang B, Yang B, Tang Z . Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004; 130(7):417-22. DOI: 10.1007/s00432-004-0552-0. View

2.
Younossi Z, Otgonsuren M, Henry L, Venkatesan C, Mishra A, Erario M . Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology. 2015; 62(6):1723-30. DOI: 10.1002/hep.28123. View

3.
Omata M, Cheng A, Kokudo N, Kudo M, Lee J, Jia J . Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017; 11(4):317-370. PMC: 5491694. DOI: 10.1007/s12072-017-9799-9. View

4.
Kobi M, Paroder V, Flusberg M, Rozenblit A, Chernyak V . Limitations of GD-EOB-DTPA-enhanced MRI: can clinical parameters predict suboptimal hepatobiliary phase?. Clin Radiol. 2016; 72(1):55-62. DOI: 10.1016/j.crad.2016.10.004. View

5.
Estes C, Anstee Q, Arias-Loste M, Bantel H, Bellentani S, Caballeria J . Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol. 2018; 69(4):896-904. DOI: 10.1016/j.jhep.2018.05.036. View